PMID- 28146431
OWN - NLM
STAT- MEDLINE
DCOM- 20171004
LR  - 20221207
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 9
DP  - 2017 Feb 28
TI  - Association of plasma ghrelin levels and ghrelin rs4684677 polymorphism with mild 
      cognitive impairment in type 2 diabetic patients.
PG  - 15126-15135
LID - 10.18632/oncotarget.14852 [doi]
AB  - BACKGROUND AND AIMS: People with insulin resistance and type 2 diabetes mellitus 
      (T2DM) are at increased risks of cognitive impairment. We aimed to investigate 
      the association of plasma ghrelin levels and ghrelin rs4684677 polymorphism with 
      mild cognitive impairment (MCI) in T2DM patients. RESULTS: In addition to 
      elevated glycosylated hemoglobin (HbA1c), fasting blood glucose (FBG) and 
      homeostasis model assessment of insulin resistance (HOMA-IR), T2DM patients with 
      MCI had decreased plasma ghrelin levels compared with their healthy-cognition 
      subjects (all p < 0.05). Further logistic regression analysis showed that ghrelin 
      level was one of independent factors for MCI in T2DM patients (p < 0.05). 
      Moreover, partial correlation analysis demonstrated that ghrelin levels were 
      positively associated with the scores of Montreal Cognitive Assessment (r = 
      0.196, p = 0.041) and Auditory Verbal Learning Test-delayed recall (r = 0.197, p 
      = 0.040) after adjustment for HbA1c, FBG and HOMA-IR, wherein the latter 
      represented episodic memory functions. No significant differences were found for 
      the distributions of genotype and allele of ghrelin rs4684677 polymorphism 
      between MCI and control group. MATERIALS AND METHODS: A total of 218 T2DM 
      patients, with 112 patients who satisfied the MCI diagnostic criteria and 106 who 
      exhibited healthy cognition, were enrolled in this study. Demographic 
      characteristics, clinical variables and cognitive performances were extensively 
      assessed. Plasma ghrelin levels and ghrelin rs4684677 polymorphism were also 
      determined. CONCLUSIONS: Our results suggest that decreased ghrelin levels are 
      associated with MCI, especially with episodic memory dysfunction in T2DM 
      populations.
FAU - Huang, Rong
AU  - Huang R
AD  - Department of Endocrinology, Affiliated ZhongDa Hospital of Southeast University, 
      Nanjing, PR China, 210009.
AD  - Medical School of Southeast University, Nanjing, PR China, 210009.
FAU - Han, Jing
AU  - Han J
AD  - Department of Endocrinology, Affiliated ZhongDa Hospital of Southeast University, 
      Nanjing, PR China, 210009.
FAU - Tian, Sai
AU  - Tian S
AD  - Department of Endocrinology, Affiliated ZhongDa Hospital of Southeast University, 
      Nanjing, PR China, 210009.
FAU - Cai, Rongrong
AU  - Cai R
AD  - Department of Endocrinology, Affiliated ZhongDa Hospital of Southeast University, 
      Nanjing, PR China, 210009.
FAU - Sun, Jie
AU  - Sun J
AD  - Department of Endocrinology, Affiliated ZhongDa Hospital of Southeast University, 
      Nanjing, PR China, 210009.
FAU - Shen, Yanjue
AU  - Shen Y
AD  - Department of Endocrinology, Affiliated ZhongDa Hospital of Southeast University, 
      Nanjing, PR China, 210009.
FAU - Wang, Shaohua
AU  - Wang S
AD  - Department of Endocrinology, Affiliated ZhongDa Hospital of Southeast University, 
      Nanjing, PR China, 210009.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Biomarkers)
RN  - 0 (Ghrelin)
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/*analysis
MH  - Case-Control Studies
MH  - Cognitive Dysfunction/blood/*diagnosis/etiology
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Female
MH  - Follow-Up Studies
MH  - Genotype
MH  - Ghrelin/*blood/*genetics
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Insulin Resistance
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Genetic/*genetics
MH  - Prognosis
PMC - PMC5362472
OTO - NOTNLM
OT  - ghrelin
OT  - mild cognitive impairment
OT  - polymorphism
OT  - type 2 diabetes mellitus
COIS- CONFLICTS OF INTEREST All authors declare that there are no conflicts of 
      interest.
EDAT- 2017/02/02 06:00
MHDA- 2017/10/05 06:00
PMCR- 2017/02/28
CRDT- 2017/02/02 06:00
PHST- 2016/07/29 00:00 [received]
PHST- 2017/01/16 00:00 [accepted]
PHST- 2017/02/02 06:00 [pubmed]
PHST- 2017/10/05 06:00 [medline]
PHST- 2017/02/02 06:00 [entrez]
PHST- 2017/02/28 00:00 [pmc-release]
AID - 14852 [pii]
AID - 10.18632/oncotarget.14852 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Feb 28;8(9):15126-15135. doi: 10.18632/oncotarget.14852.